Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy

References

• Moreau P, Karamanesht II, Domnikova N, Kyselyova MY, Vilchevska KV, Doronin VA, Schmidt A, Hulin C, Leleu X, Esseltine DL, et al. Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. Clin Pharmacokinet 2012; 51:823 - 9; http://dx.doi.org/10.1007/s40262-012-0010-0; PMID: 23018466
   PubMed Web of Science ®Google Scholar
• Bortezomib EH. Recent Results Cancer Res 2010; 184:173 - 87; PMID: 20072838
   PubMedGoogle Scholar
• Driscoll JJ, Woodle ES. Targeting the ubiquitin+proteasome system in solid tumors. Semin Hematol 2012; 49:277 - 83; http://dx.doi.org/10.1053/j.seminhematol.2012.04.002; PMID: 22726552
   PubMed Web of Science ®Google Scholar
• Hayden MS, Ghosh S. Shared principles in NFkappaB signaling. Cell 2008; 132:344 - 62; http://dx.doi.org/10.1016/j.cell.2008.01.020; PMID: 18267068
   PubMed Web of Science ®Google Scholar
• Schwartz R, Davidson T. Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology (Williston Park) 2004; 18:Suppl 11 14 - 21; PMID: 15688598
   PubMedGoogle Scholar
• Cavaletti G, Jakubowiak AJ. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma 2010; 51:1178 - 87; http://dx.doi.org/10.3109/10428194.2010.483303; PMID: 20497001
   PubMed Web of Science ®Google Scholar
• Berkowitz A, Walker S. Bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Clin J Oncol Nurs 2012; 16:86 - 9; http://dx.doi.org/10.1188/12.CJON.86-89; PMID: 22297012
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 2012; 82:51 - 77; http://dx.doi.org/10.1016/j.critrevonc.2011.04.012; PMID: 21908200
   PubMed Web of Science ®Google Scholar
• Lanzani F, Mattavelli L, Frigeni B, Rossini F, Cammarota S, Petrò D, Jann S, Cavaletti G. Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity. J Peripher Nerv Syst 2008; 13:267 - 74; http://dx.doi.org/10.1111/j.1529-8027.2008.00192.x; PMID: 19192066
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, San-Miguel JF, Anderson KC. Emerging therapies for the treatment of relapsed or refractory multiple myeloma. Eur J Haematol 2011; 86:1 - 15; http://dx.doi.org/10.1111/j.1600-0609.2010.01542.x; PMID: 20942854
   PubMed Web of Science ®Google Scholar
• Brix Finnerup N, Hein Sindrup S, Staehelin Jensen T. Management of painful neuropathies. Handb Clin Neurol 2013; 115:279 - 90; http://dx.doi.org/10.1016/B978-0-444-52902-2.00017-5; PMID: 23931787
   PubMedGoogle Scholar
• Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009; 27:3518 - 25; http://dx.doi.org/10.1200/JCO.2008.18.3087; PMID: 19528374
   PubMed Web of Science ®Google Scholar
• Mateos MV, San Miguel JF. Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma. Ther Adv Hematol 2012; 3:117 - 24; http://dx.doi.org/10.1177/2040620711432020; PMID: 23556118
   PubMedGoogle Scholar
• Thompson JL. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma. Ann Pharmacother 2013; 47:56 - 62; http://dx.doi.org/10.1345/aph.1R561; PMID: 23300152
   PubMed Web of Science ®Google Scholar
• Pautasso C, Bringhen S, Cerrato C, Magarotto V, Palumbo A. The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma. Expert Opin Drug Metab Toxicol 2013; 9:1371 - 9; http://dx.doi.org/10.1517/17425255.2013.817556; PMID: 23834482
   PubMed Web of Science ®Google Scholar
• Bazzaro M, Lin Z, Santillan A, Lee MK, Wang MC, Chan KC, Bristow RE, Mazitschek R, Bradner J, Roden RB. Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. Clin Cancer Res 2008; 14:7340 - 7; http://dx.doi.org/10.1158/1078-0432.CCR-08-0642; PMID: 19010849
   PubMed Web of Science ®Google Scholar
• Staff NP, Podratz JL, Grassner L, Bader M, Paz J, Knight AM, Loprinzi CL, Trushina E, Windebank AJ. Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons. Neurotoxicology 2013; 39:124 - 31; http://dx.doi.org/10.1016/j.neuro.2013.09.001; PMID: 24035926
   PubMed Web of Science ®Google Scholar
• Meregalli C, Canta A, Carozzi VA, Chiorazzi A, Oggioni N, Gilardini A, Ceresa C, Avezza F, Crippa L, Marmiroli P, et al. Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats. Eur J Pain 2010; 14:343 - 50; http://dx.doi.org/10.1016/j.ejpain.2009.07.001; PMID: 19695912
   PubMed Web of Science ®Google Scholar
• Carozzi VA, Canta A, Oggioni N, Sala B, Chiorazzi A, Meregalli C, Bossi M, Marmiroli P, Cavaletti G. Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies. Exp Neurol 2010; 226:301 - 9; http://dx.doi.org/10.1016/j.expneurol.2010.09.004; PMID: 20832406
   PubMed Web of Science ®Google Scholar
• Bruna J, Udina E, Alé A, Vilches JJ, Vynckier A, Monbaliu J, Silverman L, Navarro X. Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice. Exp Neurol 2010; 223:599 - 608; http://dx.doi.org/10.1016/j.expneurol.2010.02.006; PMID: 20188093
   PubMed Web of Science ®Google Scholar
• Huff LM, Sackett DL, Poruchynsky MS, Fojo T. Microtubule-disrupting chemotherapeutics result in enhanced proteasome-mediated degradation and disappearance of tubulin in neural cells. Cancer Res 2010; 70:5870 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-09-4281; PMID: 20587529
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, Cortinovis D, Bidoli P. Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 2010; 46:479 - 94; http://dx.doi.org/10.1016/j.ejca.2009.12.008; PMID: 20045310
   PubMed Web of Science ®Google Scholar
• Shin YK, Jang SY, Lee HK, Jung J, Suh DJ, Seo SY, Park HT. Pathological adaptive responses of Schwann cells to endoplasmic reticulum stress in bortezomib-induced peripheral neuropathy. Glia 2010; 58:1961 - 76; http://dx.doi.org/10.1002/glia.21065; PMID: 20830808
   PubMed Web of Science ®Google Scholar
• Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008; 13:27 - 46; http://dx.doi.org/10.1111/j.1529-8027.2008.00156.x; PMID: 18346229
   PubMed Web of Science ®Google Scholar
• Poruchynsky MS, Sackett DL, Robey RW, Ward Y, Annunziata C, Fojo T. Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition. Cell Cycle 2008; 7:940 - 9; http://dx.doi.org/10.4161/cc.7.7.5625; PMID: 18414063
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Gilardini A, Canta A, Rigamonti L, Rodriguez-Menendez V, Ceresa C, Marmiroli P, Bossi M, Oggioni N, D’Incalci M, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 2007; 204:317 - 25; http://dx.doi.org/10.1016/j.expneurol.2006.11.010; PMID: 17214983
   PubMed Web of Science ®Google Scholar
• Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005; 8:407 - 19; http://dx.doi.org/10.1016/j.ccr.2005.10.013; PMID: 16286248
   PubMed Web of Science ®Google Scholar
• Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 2004; 22:304 - 11; http://dx.doi.org/10.1081/CNV-120030218; PMID: 15199612
   PubMed Web of Science ®Google Scholar
• Casafont I, Berciano MT, Lafarga M. Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons. Neurotox Res 2010; 17:167 - 78; http://dx.doi.org/10.1007/s12640-009-9086-1; PMID: 19609631
   PubMed Web of Science ®Google Scholar
• Palanca A, Casafont I, Berciano MT, Lafarga M. Proteasome inhibition induces DNA damage and reorganizes nuclear architecture and protein synthesis machinery in sensory ganglion neurons. Cell Mol Life Sci 2013; http://dx.doi.org/10.1007/s00018-013-1474-2; PMID: 24061536
   PubMed Web of Science ®Google Scholar
• Reece DE, Sullivan D, Lonial S, Mohrbacher AF, Chatta G, Shustik C, Burris H 3rd, Venkatakrishnan K, Neuwirth R, Riordan WJ, et al. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemother Pharmacol 2011; 67:57 - 67; http://dx.doi.org/10.1007/s00280-010-1283-3; PMID: 20306195
   PubMed Web of Science ®Google Scholar
• McConkey DJ, White M, Yan W. HDAC inhibitor modulation of proteotoxicity as a therapeutic approach in cancer. Adv Cancer Res 2012; 116:131 - 63; PMID: 23088870
   PubMed Web of Science ®Google Scholar
• Steffen J, Seeger M, Koch A, Krüger E. Proteasomal degradation is transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop. Mol Cell 2010; 40:147 - 58; http://dx.doi.org/10.1016/j.molcel.2010.09.012; PMID: 20932482
   PubMed Web of Science ®Google Scholar
• Contini A, Cappelletti G, Cartelli D, Fontana G, Gelmi ML. Molecular dynamics and tubulin polymerization kinetics study on 1,14-heterofused taxanes: evidence of stabilization of the tubulin head-to-tail dimer-dimer interaction. Mol Biosyst 2012; 8:3254 - 61; http://dx.doi.org/10.1016/j.molcel.2010.09.012; PMID: 20932482
   PubMed Web of Science ®Google Scholar
• LaPointe NE, Morfini G, Brady ST, Feinstein SC, Wilson L, Jordan MA. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology 2013; 37:231 - 9; http://dx.doi.org/10.1016/j.neuro.2013.05.008; PMID: 23711742
   PubMed Web of Science ®Google Scholar
• Tulub AA, Stefanov VE. Cisplatin stops tubulin assembly into microtubules. A new insight into the mechanism of antitumor activity of platinum complexes. Int J Biol Macromol 2001; 28:191 - 8; http://dx.doi.org/10.1016/S0141-8130(00)00159-8; PMID: 11251225
   PubMed Web of Science ®Google Scholar
• Ceresa C, Giovannetti E, Voortman J, Laan AC, Honeywell R, Giaccone G, Peters GJ. Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells. Mol Cancer Ther 2009; 8:1026 - 36; http://dx.doi.org/10.1158/1535-7163.MCT-08-0700; PMID: 19383850
   PubMed Web of Science ®Google Scholar
• Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004; 22:2108 - 21; http://dx.doi.org/10.1200/JCO.2004.02.106; PMID: 15169797
   PubMed Web of Science ®Google Scholar
• Maggioni D, Nicolini G, Chiorazzi A, Meregalli C, Cavaletti G, Tredici G. Different effects of erythropoietin in cisplatin- and docetaxel-induced neurotoxicity: an in vitro study. J Neurosci Res 2010; 88:3171 - 9; http://dx.doi.org/10.1002/jnr.22465; PMID: 20722073
   PubMed Web of Science ®Google Scholar
• Scuteri A, Donzelli E, Ravasi M, Tredici G. Adult mesenchymal stem cells support cisplatin-treated dorsal root ganglion survival. Neurosci Lett 2008; 445:68 - 72; http://dx.doi.org/10.1016/j.neulet.2008.08.056; PMID: 18771708
   PubMed Web of Science ®Google Scholar
• Persohn E, Canta A, Schoepfer S, Traebert M, Mueller L, Gilardini A, Galbiati S, Nicolini G, Scuteri A, Lanzani F, et al. Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer 2005; 41:1460 - 6; http://dx.doi.org/10.1016/j.ejca.2005.04.006; PMID: 15913989
   PubMed Web of Science ®Google Scholar
• Zimmermann M. Ethical considerations in relation to pain in animal experimentation. Acta Physiol Scand Suppl 1986; 554:221 - 33; PMID: 3469880
   PubMedGoogle Scholar
• Marmiroli P, Rodriguez-Menendez V, Rigamonti L, Tonoli E, Rigolio R, Cavaletti G, Tredici G, Vercelli A. Neuropathological changes in the peripheral nervous system and spinal cord in a transgenic mouse model of Niemann-Pick disease type A. Clin Neuropathol 2009; 28:263 - 74; PMID: 19642505
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Tredici G, Marmiroli P, Petruccioli MG, Barajon I, Fabbrica D. Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol 1992; 84:364 - 71; http://dx.doi.org/10.1007/BF00227662; PMID: 1441917
   PubMed Web of Science ®Google Scholar
• Scuteri A, Nicolini G, Miloso M, Bossi M, Cavaletti G, Windebank AJ, Tredici G. Paclitaxel toxicity in post-mitotic dorsal root ganglion (DRG) cells. Anticancer Res 2006; 26:2A 1065 - 70; PMID: 16619507
   PubMed Web of Science ®Google Scholar
• Berkers CR, Verdoes M, Lichtman E, Fiebiger E, Kessler BM, Anderson KC, Ploegh HL, Ovaa H, Galardy PJ. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods 2005; 2:357 - 62; http://dx.doi.org/10.1038/nmeth759; PMID: 15846363
   PubMed Web of Science ®Google Scholar